- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05291611
Smart Sensory Technology in Psychotherapy for Pediatric OCD (SSTeP-KiZ)
Smart Sensory Technology in Telepsychotherapy for the Treatment of Obsessive-compulsive Disorder in Children and Adolescents
Telemedicine interventions enable the improvement of behavioral state-of-the-art treatment of OCD, as therapy can be delivered in the patients' immediate home environment, allowing for more valid symptom actualization. In addition, access to experts is made possible even in rural areas, and the inhibition to seek therapy can be reduced. In a preliminary study, our research group was able to demonstrate the efficiency of using telemedical access. SSTeP-KiZ aims at the further development of telemedical treatment of children with OCD by using sensor technology in the home setting, where most symptoms occur. In this context, relevant emotional states of the patients such as anxiety and stress reactions shall be quantified reliably during the therapy session with exposures by combining different sensor modalities. As a result, the therapy procedure can be immediately and individually adapted to the patient and the situation, thus optimizing the success of the treatment.
Methods: It is planned to establish the therapy system on a sample of 10 healthy children and 5-10 patients with OCD treated at University Hospital of Tübingen. Afterwards we will recruit 26 children with obsessive-compulsive disorder aged 12-18 years to conduct therapy with them. There are 14 weekly therapy sessions via teleconferencing with the children and parents. During the sessions and exposures, patients' field of view is recorded via eye trackers, measures of stress responses via heart rate and pupillometry, and movement measures for approach-avoidance behaviors. Using an AI approach, these indicators are integrated and reported back to the therapist online to optimize the therapy process. Accompanying app-based daily symptoms will also be collected by the children and parents and processed for use in the therapy process. We expect a good feasibility and significant symptom reduction by this therapeutic approach and the chance to make this system usable for broad clinical application.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The main goal of SSTeP-KiZ is the implementation of sensors in the existing telepsychotherapeutic treatment of children and adolescents with obsessive-compulsive disorder. SSTeP-KiZ aims to significantly improve the telepsychotherapeutic treatment options for this group of patients through the use of sensors that can be worn during symptom triggering situations at home in patients' everyday lives, and an analysis and incorporation of the multimodal sensor data into the therapeutic process.
In the medium term, SSTeP-KiZ should enable the use of real-time data on anxiety and stress levels (pupillometry, heart rate, eye tracking) obtained during therapy sessions by the therapist while the patient is still in the therapy session. Thus, even under the conditions of telepsychotherapy, despite the physical absence of the therapist, the individual intensity of the therapy sessions can be directly adjusted. In addition, the compliance and satisfaction of the patients during the accompanied therapy tasks can be directly promoted. Furthermore, the data obtained within the framework of SSTeP-KiZ should also be suitably prepared concerning the children and adolescents and their relatives and, in the sense of therapeutic feedback, suitably visualized to form an additional component of the therapy.
Goals:
A. Development of a prototype for a multisensory therapy system in healthy children and adaptation to mentally ill children with an obsessive-compulsive disorder.
B. Evaluation of the prototype in the context of an internet-based psychotherapy for mentally ill children with an obsessive-compulsive disorder C: Preparations for the introduction of the multisensory therapy system into broad clinical application in the health care system
Sample I: 10 healthy children:
Sample II: 5-10 patients of University Hospital Tübingen with OCD.
Sample III&IV: 6 & 20 children with OCD.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Karsten Hollmann
- Phone Number: 07071-2982292
- Email: karsten.hollmann@med.uni-tuebingen.de
Study Contact Backup
- Name: Carolin S Hohnecker
- Phone Number: 07071-2982292
- Email: carolin.hohnecker@med.uni-tuebingen.de
Study Locations
-
-
Baden-Württemberg
-
Tuebingen, Baden-Württemberg, Germany, 72076
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- children and adolescents with obsessive-compulsive disorders
- aged 12 to 18 years
- a primary DSM-5 obsessive-compulsive disorder
- at least one primary caretaker
- German-speaking (child & caretakers)
- family home equipped with broadband internet connection
- written informed consent of the child and its caretakers
- psychiatric comorbidities will be allowed as long as the comorbid disorder does not have a higher treatment priority than OCD (i.e., psychosis, eating disorder and severe depression)
- Medication is allowed if treatment was stable for 6 weeks before diagnostics and will then be taken during the trial.
Exclusion Criteria:
- IQ below 70
- patients do not speak or understand German
- patients have a psychiatric comorbidity or suicidality that makes participation clinically inappropriate
- too seriously ill so that they should be treated in the hospital
- stable social environment, able to support the children adequately during therapy. - drug addiction
- if the family seems to be severely psychologically burdened so that participation in the sessions and support of the children during the trial will not be possible
- no other psychological treatment is allowed
- If reporting side effects or circumstances that make iCBT treatment clinically inappropriate, or if wished by the patients, the patients are excluded from the study and transferred to another more appropriate therapy option.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment with cbt
Treatment for 26 patients with obsessive-compulsive disorder, 14 sessions, each about 90 minutes.
|
26 patients with obsessive-compulsive disorder (OCD) receive treatment with cognitive-behavioral therapy.
14 sessions will take place via the internet.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
System Usability Scale (SUS) - assessment of the change in the handling of the technical equipment during treatment
Time Frame: After week 1, week 7 and week 14
|
Patients are to answer a total of 60 questions with 10 questions for each technical device from the system usability scale (SUS), regarding the handling of the technical equipment and to capture the change in it.
|
After week 1, week 7 and week 14
|
Therapy Process Questionnaire (TPQ) - assessing the stability of the therapeutic relationship and possible changes in the treatment process
Time Frame: Weekly after each therapy session, for 14 weeks of therapy
|
Patients are to rate how they perceive the therapeutic process.
|
Weekly after each therapy session, for 14 weeks of therapy
|
Client Satisfaction Questionnaire-8 (CSQ-8)
Time Frame: After the last session in week 14 (post treatment)
|
We assess participant's perceptions of the value of the treatment they received
|
After the last session in week 14 (post treatment)
|
Questionnaire for the evaluation of the treatment (FBB)
Time Frame: After the last session in week 14 (post treatment)
|
It records how satisfied the participants were with the treatment.
We reduced the total number of questions from 20 to 17, as 3 items covered circumstances that did not occur in the context of internet-based therapy.
|
After the last session in week 14 (post treatment)
|
Change in Health Care Utilization, measured by HCU-Q (Health Care Utilization-Questionnaire)
Time Frame: Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
|
Questionnaire to capture costs and time spent on online-based treatments; Health Care Utilization-Questionnaire, change is assessed between baseline and the last session.
|
Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
|
Change in Quality of Life: EQ-5D-3L (European Quality of Life Five Dimensions Questionnaire)
Time Frame: Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
|
Questionnaire to capture costs and time spent on online-based treatments: Questionnaire to capture costs and time spent on online-based treatments, measured by European Quality of Life Five Dimensions Questionnaire Three Level Version (EQ-5D-3L).
|
Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
|
Change in costs spent on online interventions: CIIQ (Caregiver Indirect and Informal Care Cost Assessment Questionnaire)
Time Frame: Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
|
Questionnaire to capture costs and time spent on online-based treatments: Caregiver Indirect and Informal Care Cost Assessment Questionnaire (CIIQ)
|
Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
|
Change in affinity for technology (TA-EG)
Time Frame: Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
|
Technology Affinity Questionnaire (TA-EG): The TA-EG can be answered by patients and their parents and contains 19 items.
It measures the attitude towards and use of electronic devices.
|
Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
|
Change in attitudes toward and satisfaction with telemedicine psychotherapy (EZtP)
Time Frame: Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
|
Questionnaire on the Attitude and Satisfaction of Telemedicine Psychotherapy (EZtP).
The EZtP is a self-developed questionnaire that measures attitudes to and satisfaction with telemedicine psychotherapy.
It can be answered by both the adolescents and the parents.
|
Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
|
Barriers to Treatment Participation Scale (BTPS)
Time Frame: Once after treatment (t1, after 14 weeks)
|
The Barriers to Treatment Participation Scale, is a 44 item rating of how much parents agree with statements about their expectancies of barriers to treatment participation for their child, using a 5-point Likert scale (1=totally disagree, 5= totally agree).
|
Once after treatment (t1, after 14 weeks)
|
Measures of feasibility: Manual Rating Form (MRF)
Time Frame: Once after treatment (t1, after 14 weeks)
|
The Manual Rating Form (MRF) is used to assess feasibility of the manual.
|
Once after treatment (t1, after 14 weeks)
|
Measures of feasibility: Summary Therapist Feedback Form (STFF)
Time Frame: Once after treatment (t1, after 14 weeks)
|
The Summary Therapist Feedback Form (STFF) is used to assess the ease of manual implementation completed after each case.
|
Once after treatment (t1, after 14 weeks)
|
Implementation and satisfaction questionnaire for the children
Time Frame: Once after treatment (t1, after 14 weeks)
|
We designed an implementation and satisfaction questionnaire for the children.
It covers the subject's dosage, quality, adaption, responsiveness and program differentiation.
|
Once after treatment (t1, after 14 weeks)
|
Implementation and satisfaction questionnaire for the parents
Time Frame: Once after treatment (t1, after 14 weeks)
|
We designed an implementation and satisfaction questionnaire for the parents.
It covers the subject's dosage, quality, adaption, responsiveness and program differentiation.
|
Once after treatment (t1, after 14 weeks)
|
Implementation and satisfaction questionnaire for the therapist
Time Frame: Once after treatment (t1, after 14 weeks)
|
We designed an implementation and satisfaction questionnaire for the therapist.
Questions regarding whether the intervention was being delivered as written (adherence) and the representativeness of the participants (reach) were implemented in the therapist's questionnaire covering questions like "The psychoeducation/relapse prophylaxis/exposure sessions were carried out as planned."
and a checklist regarding information e.g. about the socioeconomic status, age, gender or IQ.
|
Once after treatment (t1, after 14 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)
Time Frame: Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
|
The CY-BOCS is a clinician-administered instrument that evaluates obsessions and compulsions separately on time consumed, distress, interference, resistance, and control.
A score higher than 16 describes clinical relevant obsessive-compulsive symptoms.
The short form of the CY-BOCS is conducted daily on the app as part of the mobile assessment.
|
Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
|
Children's Global Assessment Scale (CGAS)
Time Frame: Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
|
The CGAS is a clinician's rating of the patient's overall level of functional strain.
|
Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
|
Clinical Global Impressions-Improvement (CGI-I)
Time Frame: Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
|
The CGI-I is used to assess overall clinical improvement based on symptoms observed and impairment reported.
The clinical-rated scale has been used successfully in patients with OCD.
|
Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
|
Clinical Global Impressions-Severity (CGI-S)
Time Frame: Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
|
Is a clinical rating of symptom severity.
The CGI-S correlates strongly with the CY-BOCS total score in pediatric OCD patients, and is widely used and has been shown to be treatment sensitive.
|
Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
|
Children's DIPS Open Access: Diagnostic Interview in Childhood and Adolescent Mental Disorders (Kinder-DIPS)
Time Frame: Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
|
The Kinder-DIPS is a structured clinical interview for the diagnosis of mental disorders.
There is a child version and a parent version.
Both, the child version and the parent version, are performed.
|
Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
|
Brief Self-Control Scale
Time Frame: After week 1, week 7 and week 14
|
Patients will be given questions concerning self-control (Brief Self-Control Scale, German Version (Sproesser et al., 2011))
|
After week 1, week 7 and week 14
|
Self-efficacy
Time Frame: After week 1, week 7 and week 14
|
Patients answer questions regarding self-efficacy according to the questionnaire of Schwarzer & Jerusalem (1999).
|
After week 1, week 7 and week 14
|
Coping strategies
Time Frame: After week 1, week 7 and week 14
|
Patients answer questions regarding coping strategies according to the questionnaire of Schwarzer & Jerusalem (1999).
|
After week 1, week 7 and week 14
|
Self-regulation
Time Frame: After week 1, week 7 and week 14
|
Patients answer questions regarding self-regulation according to the questionnaire of Schwarzer & Jerusalem (1999).
|
After week 1, week 7 and week 14
|
Procrastination
Time Frame: After week 1, week 7 and week 14
|
Patients answer questions regarding procrastination according to the questionnaire of Schwarzer & Jerusalem (1999).
|
After week 1, week 7 and week 14
|
Child Behavior Checklist (CBCL)
Time Frame: Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
|
The Child Behaviour Checklist (CBCL/6-18R) is used to record behavioural problems, emotional problems, somatic complaints as well as social competences of children and adolescents of school age from the parents' point of view.
|
Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
|
Youth Self-Report (YSR)
Time Frame: Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
|
The YSR/11-18R (youth version) was derived directly from the CBCL and allows an assessment of the largely identical characteristics from the perspective of adolescents.
|
Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
|
Child Obsessive-Compulsive Impact Scale (COIS-RC)
Time Frame: Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
|
The COIS-RC Culture includes a parent and a child report.
It is a 33-item questionnaire designed to assess the impact of OCD symptoms on the psychosocial functioning of children and adolescent in home, social, and academic environments.
|
Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
|
Fair Intelligence Test (CFT 20-R)
Time Frame: Baseline (t0) before treatment
|
The CFT 20-R records the basic intelligence according to the general fluid ability.
|
Baseline (t0) before treatment
|
Questionnaire for self-assessment of depressive disorders (DISYPS-III SBB- DES)
Time Frame: Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
|
The SBB-DES (DYSIPS-III) is a self-report questionnaire for adolescents (11 to 18 years) and part of the Diagnostic System for Mental Disorders according to ICD-10 and DSM-5 for children and adolescents.
It records the different symptoms of a depressive disorder, the extent of distress and the competencies of the adolescent.
|
Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
|
Screen for Child Anxiety Related Emotional Disorders (SCARED)
Time Frame: Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
|
The SCARED is a psychometrically sound child- and parent-report questionnaire which assesses the presence of DSM-IV anxiety symptoms.
|
Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
|
Questionnaire for Measuring Health-Related Quality of Life in Children and Adolescents (KIDSCREEN)
Time Frame: Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
|
The questionnaires can be used to assess the subjective health and well-being of children and adolescents aged 8 to 18 years.
A corresponding parent version is available for parents.
|
Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
|
Ulm Quality of Life Inventory for Parents of Chronically Ill Children (ULQUIE)
Time Frame: Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
|
The ULQUIE was used to record the quality of life of the parents.
|
Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
|
Affect questionnaire
Time Frame: Daily after each therapy session (approximately 5-10 minutes), for a time period of 14 weeks of therapy
|
The emotional state of the patients is recorded daily by the app (ambulatory assessment)
|
Daily after each therapy session (approximately 5-10 minutes), for a time period of 14 weeks of therapy
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Annette Conzelmann, Prof., University Hospital Tübingen
- Principal Investigator: Tobias J Renner, Prof., University Hospital Tübingen
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 877/2020BO1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obsessive-Compulsive Disorder
-
Anne Katrine PagsbergCopenhagen Trial Unit, Center for Clinical Intervention Research; Danish Research...Active, not recruitingObsessive-Compulsive Disorder in Children | Obsessive-Compulsive Disorder in AdolescenceDenmark
-
Baylor College of MedicineRecruitingObsessive-Compulsive Disorder | Cognitive Behavioral Therapy | Obsessive-Compulsive Disorder in Children | Obsessive-Compulsive Disorder in AdolescenceUnited States
-
Chaim HuijserLevvelRecruitingObsessive-Compulsive Disorder | Anxiety Disorders and Symptoms | Obsessive-Compulsive Disorder in Children | Obsessive-Compulsive Disorder in AdolescenceNetherlands
-
Stanford UniversityCompletedObsessive Compulsive DisorderUnited States
-
NYU Langone HealthCompletedObsessive Compulsive DisorderUnited States
-
Massachusetts General HospitalActive, not recruitingObsessive Compulsive DisorderUnited States
-
Boston University Charles River CampusCompletedObsessive Compulsive DisorderUnited States
-
Butler HospitalNational Institute of Mental Health (NIMH)CompletedObsessive Compulsive DisorderUnited States
-
Karolinska InstitutetCompletedObsessive Compulsive DisorderSweden
-
Roseli ShavittCompleted
Clinical Trials on Online-based Cognitive-behavioral Therapy for OCD
-
Massachusetts General HospitalUniversity of California, San FranciscoCompleted
-
Shanghai Mental Health CenterNot yet recruitingFeeding and Eating DisordersChina
-
Karolinska InstitutetKarolinska University HospitalActive, not recruiting
-
University of ZurichUnknownUnipolar DepressionSwitzerland
-
George Washington UniversityCompletedInsomnia | Breast Cancer FemaleUnited States
-
Stanford UniversityNational Institute of Nursing Research (NINR)Completed
-
Hong Kong Baptist UniversityStockholm University; Research Grants Council, Hong Kong; Richmond Fellowship... and other collaboratorsRecruitingSocial Anxiety DisorderHong Kong
-
University of KentuckyPatient-Centered Outcomes Research Institute; University of California, Los...Active, not recruitingHeart Diseases | Depressive SymptomsUnited States
-
Icahn School of Medicine at Mount SinaiNational Institute for Occupational Safety and Health (NIOSH/CDC)CompletedPost-Traumatic Stress DisorderUnited States
-
CHA UniversityEnrolling by invitationCancer | Psychological Distress | Cancer Pain | Distress, Emotional | Therapy-Associated Cancer | Psychiatric or Mood Diseases or ConditionsKorea, Republic of